In vitro 14-day cultures of peripheral blood mononuclear cells from hairy cell leukemia patients consistently showed the presence of hematopoietic stem cells giving rise to multilineage colonies containing a high proportion of lymphoid cells associated with the myeloid and erythroid progenitors. These stem cells are not the hairy cells but appear to be pluripotent lymphomyeloid primitive stem cells persisting in this leukemia. Interferon ac or .f1 did not inhibit the growth of these colonies, as they did the growth of colonies of normal hematopoietic progenitors, but markedly decreased the ratio of lymphoid to myelomonocytic cells, by increasing the formation of monocytes and other nonlymphoid cell types in these multilineage colonies. Interferon ydid not have the same effects on differentiation.
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The existence of hematopoietic primitive stem cells giving rise to the lymphoid progeny, as well as to the other blood cell lineages, has been inferred from the genetic study ofleukemia clones in vivo (1), and these rare cells seem to be detectable in a few hematopoietic disorders. Thus, cultures of bone marrow (BM) and peripheral blood mononuclear cells (PBMC) from non-Hodgkin lymphoma and chronic myelogenous leukemia patients may produce multilineage colonies with lymphoid and myeloid cells (2, 3) . We have studied hematopoiesis in cells from patients with hairy cell leukemia (HCL), a disease characterized by pancytopenia and, in BM, spleen, and often peripheral blood, by accumulation of incompletely differentiated, preplasmatic B lymphocytes with low proliferation, with typical morphology, and also with the interleukin 2 receptor Tac antigens as well as unexplained monocyte markers (4) (5) (6) . Long-term interferon (IFN) a injections can reduce the hairy cell mass but, more strikingly, restore the levels of granulocytes, macrophages, platelets, and erythrocytes in HCL patients (7) (8) (9) .
In vitro hematopoietic colony cultures from the peripheral blood of HCL patients consistently had multilineage colonies containing many B lymphocytes associated with the myeloid cells but poor in monocytes. These colony-forming cells are distinct from the hairy cells. Type I human recombinant IFN-a or -,3 profoundly affects the differentiation pattern of the HCL lymphomyeloid stem cell cultures: the formation of myeloid and monocytic elements, as well as the formation of normoblasts and megakaryocytes, is enhanced, whereas the number of lymphoid cells decreases. Type II IFN-y has no such effect. These findings may be related to the mechanism by which type I IFNs induce remission and relieve pancytopenia in HCL patients. HCL provides an experimental model for the study of primitive multilineage lymphomyeloid stem cells growth and differentiation and for the study of the effects of IFN on this process.
MATERIALS AND METHODS
Colony-Forming Cultures for Hematopoietic Progenitors. Cells were cultured essentially as described (3, 10) . PBMC were separated from heparinized blood by Ficoll/Hypaque (Pharmacia) centrifugation and washed. Cells that did not adhere to plastic dishes after 2 hr were plated at 4 x 105 cells per ml in Iscove's modified Dulbecco's medium (IMDM, GIBCO) with 20% (vol/vol) fresh human plasma (single donor), 0.9% methyl cellulose, 20 ,uM 2-mercaptoethanol, erythropoietin at 0.5 unit/ml (step III, Connaught Laboratories, Willowdale, ON), and 10% (vol/vol) fetal calf serum supplemented by 7.5% (vol/vol) phytohemagglutinin-stimulated leukocyte conditioned medium [supernatant of PBMC from healthy donors after 7 days of culture at 106 cells per ml with 1% phytohemagglutinin in IMDM and 10% (vol/vol) fetal calf serum], as the source of multicolony-stimulating factors. Formation of colonies (10, 11) was followed for 14 days at 37°C in humidified 5% C02/95% air. Where indicated, recombinant (r) IFN-ac, produced in Escherichia coli and purified to homogeneity (109 international units/mg) as described (9, 12) , was added at day 0. rIFN-,1 and rIFN-y were both produced in CHO cells and purified to homogeneity on monoclonal antibody columns as described (13, 14 Relative changes in number of colonies produced by IFNs in 14-day cultures. Absolute values are in parentheses. Average is from PBMC of four healthy donors and five HCL patients. The respective number of CFU-(L)GEMM, CFU-(L)GM, BFU-E, and colony-forming units of megakaryocytes colonies were as follows: for normal PBMC cultures, 11 ± 5, 75 ± 18, 45 ± 15, and 5 ± 1.5; and for HCL PBMC, 4.5 ± 1.5, 25 ± 5, 13 ± 5, and 1.5 ± 1. ND, not determined.
(4-8), patients had variable numbers of circulating hairy cells identified by morphology and by TRAPase; two patients had 70-80%, and eight patients had 2-15% peripheral blood hairy cells. The less-specific markers found on hairy cells (Tac, B1/RFB7, sIgG) also correlated with the abundance of hairy cells in peripheral blood while sIgM+-cells were low (0.6% + 0.8). Two patients had had a splenectomy, and one had been treated with IFN. (Table 2) . About half of the cells from these colonies bound monoclonal antibodies to the B-lymphocyte-restricted B1 and RFB7 antigens (4, 16, 17) (Table 2 ). Around 10% of the cells also bound the T-lymphocyte T2 antigen (data not shown). As usual (2, 10, 11), the colonies from healthy donors had <1% lymphoid cells by morphology or anti-Bi and RFB7 binding (Table 2 ). In HCL PBMC cultures, lymphoid cells were present in individual colonies corresponding to the normal CFU-GEMM and more abundant CFU-GM, which we have designated, therefore, CFU-LGEMM and CFU-LGM (Table  3 , experiment 1). The very low monocyte content of HCL CFU-LGEMM and CFU-LGM (2-5%) is striking in comparison with healthy donors (Tables 2 and 3) . Even in lymphoma patients, we found the mixed CFU-LGM colonies to contain 50% monocytes and 15% lymphoid cells (data not shown). selves. We took advantage of the fact that hairy cells express the B1 antigen (4) to affinity purify hairy cells from the PBMC isolated from a HCL patient with 70-80% circulating hairy cells that were also positive for RFB7, TRAPase, and Tac antigens ( Table 4 ). The Bl-positive population contained 80% of the PBMC, which must include the bulk of the hairy cells in this patient, but produced no colonies ( Table 4 ). The CFU-LGEMM and CFU-LGM were enriched in the 20%o of PBMC that was negative for the B1 antigen (Table 4) . Hence, the lymphoid cells in the culture colonies do not arise from preexisting B1 + lymphocytes or from the hairy cells. Indeed, our cultures did not show a difference in the formation of lymphomyeloid colonies from PBMC of patients with low (<5%) or high (80%) peripheral blood hairy cells. In the lymphomyeloid colonies, the low number of TRAPase+ cells as compared to total lymphoid cells ( (Fig. 1) . Such stem cells should have self-renewal capacity: indeed, cells pooled from HCL CFU-LGEMM and CFU-LGM 14-day colonies could be replated twice in methyl-cellulose giving rise again to the same proportion of CFU-LGEMM, CFU-LGM, and BFU-E with a plating efficiency of 20-30% (data not shown), indicating that some of the stem cells proliferate in the differentiating colonies.
RESULTS
The formation oflymphoid cells in the mixed colonies does not seem to result from the presence of hairy cells or a factor they specifically produce. When either irradiated hairy cells or conditioned medium from phytohemagglutinin-stimulated HCL spleen cells (90% hairy cells) was used for the cultures of normal BM cells, lymphoid cells were still virtually absent (4%) in the normal CFU-GM and -GEMM colonies, and no significant change was seen in the growth of lymphomyeloid colonies from HCL PBMC as compared to normal conditioned medium (data not shown).
Effects of Interferons on Growth and Differentiation of Stem
Cells in HCL. Addition of rIFN-a, at 100 units/ml during the 14-day cultures of HCL PBMC strongly influenced the composition of the multilineage lymphomyeloid colonies.
The number of cells with lymphoid morphology decreased markedly in CFU-LGM, whereas the myeloid cells, and more strikingly the rare monocytes, increased ( Table 2 ). The decrease in B-lymphoid cells was confirmed by staining for the B1 and RFB7 antigens ( Table 2 ) and was seen in both CFU-LGEMM and CFU-LGM (Table 3 , experiment 1). The increase in monocytes, as well as in myeloid cells, was not only in percentage but also in absolute numbers since neither the size of the colonies nor the number of CFU-LGEMM and -LGM colonies was significantly changed by this concentration of IFN-ac (Tables 1 and 3 ). As seen, HCL BFU-E were also not reduced. IFN-a also did not prevent the self-renewal of HCL stem cells in the colonies (data not shown). With normal PBMC, rIFN-ac at 100 units/ml decreased the CFU-GEMM, -GM, and the BFU-E (Table 1) , but had no effect on the composition of the normal CFU-GM, in contrast to the HCL CFU-LGM (Table 2 ).
In HCL PBMC cultures, rIFN-/3l also reduced the number of lymphoid cells in the multilineage colonies and increased the other cell types in particular monocytes and erythroid cells (normoblasts) ( Table 3 , experiment 2). Despite variations between cultures, these effects were reproducibly observed (Table 5) . Again, these changes reflect real increases in nonlymphoid cells as the growth of the CFU-LGEMM and -LGM and ofthe BFU-E from HCL PBMC was even slightly increased by IFN-,31, in contrast to normal PBMC cultures (Table 1 ). The effect of rIFN-y was studied using conditioned medium depleted of IFN-y by affinity chromatography using high-affinity anti-IFN-y monoclonal antibodies (19) . Under these conditions, formation of lymphoid cells in the HCL-mixed colonies was somewhat reduced (Table 5 , experiment 1) and when rIFN-y was added back, in contrast to the effects of IFN-ac and -lB3 it increased slightly, but reproducibly, the number of lymphoid cells at the expense of myeloid cells (Table 5) . At 500 units/ml, the ratio of myeloid and monocytic cells to B-lymphoid cells was six times higher with rIFN-PB than with rIFN--y (Table 5, experiment 2). IFN-y at 500 units/ml started to inhibit the growth of colonies, in particular BFU-E from HCL PBMC, but had no effect at 100 units/ml where it inhibited colony growth of normal PBMC (Table 1) as reported (20, 21) .
DISCUSSION
The hairy cells, which accumulate in HCL, have been characterized as preplasmatic B lymphocytes (4). These cells are not highly proliferative and do not respond well to B mitogens, although they can be stimulated by B-cell growth factor (6). IFN-a therapy of HCL patients not only decreases the hairy cell mass but also, more important, improves the associated pancytopenia (7-9), often before the hairy cells disappear from the BM (22) . The increase in granulocytes, macrophages, platelets, and erythrocytes produced by IFN-a is rather specific for HCL and contrasts with the leucopenia seen in other patients treated by IFN-a (23) . For (2) and chronic myelogenous leukemias (3), by the persistence of primitive pluripotent stem cells CFU-LGEMM (Fig. 1) , which in our culture conditions can differentiate into myeloid and erythroid cells and into the lymphocyte lineages, mainly to pre-B lymphocytes and beyond. As the lymphoid cells Proc. Natl. Acad. Sci. USA 84 (1987) 2311 persist in CFU-GM, the HCL stem cells may not lose their lymphoid potential even after partial commitment. Moreover, the virtual absence of monocytes (contrasting to normal or lymphoma cases) suggests a defect in monocytic differentiation in HCL; interestingly, monocyte markers are detected on the B hairy cells (4) . It is tempting to see the persistence of lymphomyeloid stem cells producing many B cells as the cause of the accumulation of partially differentiated nonproliferating hairy cells due to some defect in stem cell differentiation either humoral or cellular (Fig. 1 ). An important question is whether the HCL CFU-LGEMM are analogous to the primitive stem cell giving rise to all normal blood cell lineages (1, 2) . In healthy individuals, such pluripotent stem cells could be difficult to detect in BM or PBMC because they rapidly differentiate into CFU-GEMM or because the lymphoid progenitors do not develop in culture as in HCL. Feeder-layer cultures forming B lymphocytes from mouse BM have been reported (24) .
Formation of the mixed lymphomyeloid colonies and ofthe BFU-E equivalent from HCL PBMC was not inhibited by IFN-a and -,31. In this respect also, the HCL stem cells differ from the normal hematopoietic progenitors CFU-GEMM, CFU-GM, and BFU-E of healthy donors, which were reduced by these IFNs, in line with other reports (20, 21, 25) , and even differ from those in lymphomas and chronic myelogenous leukemias that were inhibited by IFN-a under our culture conditions (unpublished results). However, IFNa and -,31 had unexpected marked effects on the fate of the lymphomyeloid colonies from HCL since they reduced the formation of B-lymphoid cells and consistently increased the number of monocytes, of myeloid and erythroid elements, and of megakaryocytes, albeit to various degrees. Although normal colonies were not restored, IFN-a and -/3 acted as if they relieved a block in differentiation of the CFU-LGEMM, -LGM stem cells toward the nonlymphoid lineages, thereby decreasing lymphogenesis (Fig. 1) . Such an IFN effect on stem cell differentiation could explain the rapid restoration of all the nonlymphoid blood cell types observed during IFN-a therapy ofHCL patients (7) (8) (9) 22) better than models in which IFN would act simply by inhibiting growth of hairy cells (6) . Interestingly, in a patient who ceased to respond to continuous IFN-a therapy after a year, we observed that IFN-a, in vitro inhibited hematopoietic colony formation and failed to reduce the B cells or to increase the myelomonocytes (unpublished observations). IFN-y, in contrast to type I IFNs, did not increase myelomonocytes or erythroid cells but rather increased the lymphocytes in the lymphomyeloid HCL colonies; IFN-y is also not efficient in HCL therapy and in vitro can act as a B-cell maturation factor (26) . Stimulation of differentiation and growth of certain leukemia cells by IFNs has been observed (25, 27, 28) . Autocrine IFN-,3 species are made during erythroid and myelomonocytic differentiation and appear to arrest growth at the end of the terminal differentiation process (29) (30) (31) . The absence of inhibition of CFU-LGEMM, -LGM, and BFU-E growth in HCL by IFN-a or -(3 may be the result of the primitive differentiation stage of the cells or of the malignant transformation. Study of the mechanisms of action of type I and II IFNs on hematopoiesis in HCL, which may be direct on stem cells or indirect through other cell types, will now require the isolation of the lymphomyeloid stem cells. Isolated stem cells from patients with HCL could also shed light on the early steps in normal hematopoiesis.
